Every 8-K that BIO-PATH HOLDINGS INC (BPTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BPTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BPTH filings page.
Bio-Path Holdings, Inc. reported unregistered equity sales under its Tier 1 Regulation A program, selling 466,100 and 489,200 common shares for net proceeds of $13,983 and $14,676, with capacity to raise an additional $571,341. The board approved a new Series B Preferred stock class with 5,000,000 authorized shares, each convertible into 1,000 common shares, voting on an as-converted basis and carrying a par value of $0.01.
The company describes a strategic turnaround that may include restarting drug trials, monetizing its oncology intellectual property, and building a digital asset treasury. MD Anderson Cancer Center agreed to restart Phase 2 AML trials if Bio-Path pays past-due balances of $292,264.21 and $63,286.55. Bio-Path opened a Coinbase account and may allocate up to 50% of capital raised to crypto opportunities, acquired a majority stake in Himalaya Technologies, Inc. via Series B Preferred issuances valued at $670,260, and issued additional Series B shares to its CEO for software. It added altFINS founder Richard Fetyko to its advisory board and signed an LOI contemplating 2,500,000 common share equivalents and an option to buy up to 22% of altFINS for two million euros; multiple initiatives remain subject to payments, definitive agreements, and successful capital raising.
Bio-Path Holdings disclosed several strategic changes and capital-related steps. The company issued a shareholder update announcing a growth-focused repositioning, brought on new scientific advisors, engaged advisors to connect with strategic and financial investors, and canceled a previously approved 1-for-30 reverse stock split.
The Board approved a “digital asset treasury 2.0” program using AI to trade and accumulate multiple L1 and L2 blockchains and authorized opening an account with Coinbase or similar exchanges to buy, sell, and hold cryptocurrencies acquired through various channels. The Board also approved assigning to the company up to $10,000,000 of a $57,903,750 judgment, plus stated interest amounts, previously awarded to CEO Vikram Grover, with consideration to be paid in company securities when the judgment is monetized, aiming for accretion to shareholders. The company cautions there is no assurance Mr. Grover will obtain custodianship needed to complete related transactions.
Bio-Path Holdings, Inc. reported several corporate updates. The company’s domestication to Wyoming was approved by the Wyoming Secretary of State on March 5, 2026, and it filed an amendment creating a new Series S Preferred Stock class with 51 authorized shares, each convertible into one common share and carrying 1% of the company’s diluted voting power.
Effective February 10, 2026, Bio-Path appointed Wendy M. Charles, PhD and Michael Hickey to its newly formed Scientific Advisory Board. Both entered three-year advisory agreements and each received 100,000 stock options with a $0.06 exercise price and a three-year expiration, subject to adjustment.
Bio-Path Holdings, Inc. reported several governance and strategic actions, including issuing Steel Giants Advisors LLC 51 shares of new Series S Preferred stock and 2,000,000 common stock purchase warrants in exchange for $10,000 of accrued payables. The company filed to domesticate from Delaware to Wyoming, expecting approval in March 2026, and is negotiating with creditors while evaluating restarting certain Phase 1 and Phase 2 drug trials. Bio-Path engaged Farrington Capital Group for technology and strategic support, paying $1,000 and issuing 100,000 restricted common shares, created a Strategic Advisory Board with associated option incentives, and, together with its majority holder, canceled a previously approved 1-for-30 reverse stock split, concluding it was not in shareholders’ interests.
Bio-Path Holdings (BPTH) filed an 8-K announcing a board change and financing plans. The Board accepted the resignation of Director Douglas Morris, delivered electronically on November 4, 2025 and accepted on November 13, 2025.
The company is seeking financing to support a planned turnaround that it anticipates will include updating its finance team, engaging new PCAOB auditors, hiring investment bankers to review its biotech portfolio for sale or partnerships, and pursuing strategic mergers and acquisitions. The company cautions that there can be no assurances of success. If capital cannot be raised, the company states there is substantial doubt about its ability to continue as a going concern and to remain listed on the OTC Markets or other public trading platforms.
Bio-Path Holdings (BPTH) announced leadership changes. On October 22, 2025, the Board appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and a member of the Board. The Board also accepted the resignation of Douglas Morris as Interim CEO and Interim CFO; he remains on the Board. In addition, Paul Aubert resigned as a Director.
This consolidates executive leadership under one individual while maintaining board continuity through Mr. Morris’s continued service. The filing does not include financial results or strategic updates, focusing solely on governance and leadership transitions.
On 20–22 June 2025, Bio-Path Holdings, Inc. (BPTH) disclosed a sequence of leadership departures and an immediate operational shutdown driven by acute liquidity constraints, according to its Form 8-K filing.
Founder Peter H. Nielsen resigned from every executive position—President, Chief Executive Officer, Chief Financial Officer, Treasurer, Principal Accounting Officer—as well as Chairman and director roles. Directors Heath Cleaver and Aline Sherwood also stepped down; both stated their decisions were not the result of disagreements with the Company or Board.
The remaining directors appointed Douglas P. Morris as Chairman with no compensatory changes. Concurrently the Board instituted a company-wide operational pause, furloughing most employees and suspending the majority of drug-development activities to conserve capital while it searches for new financing.
The filing reiterates prior warnings: without additional capital, Bio-Path may have to scale back or eliminate development programs, dispose of assets on unfavorable terms, or proceed to liquidation and dissolution. There is no assurance of securing funding on acceptable terms, if at all.
Overall, the 8-K signals elevated going-concern risk, abrupt leadership vacuum and potential value erosion for shareholders.